71,178 Shares in Jazz Pharmaceuticals PLC $JAZZ Acquired by Simplify Asset Management Inc.

Simplify Asset Management Inc. acquired a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 71,178 shares of the specialty pharmaceutical company’s stock, valued at approximately $12,100,000. Jazz Pharmaceuticals comprises about 0.2% of Simplify Asset Management Inc.’s investment portfolio, making the stock its 20th largest holding.

Several other institutional investors also recently bought and sold shares of JAZZ. Hilltop National Bank purchased a new position in shares of Jazz Pharmaceuticals during the 4th quarter worth $36,000. LRI Investments LLC acquired a new stake in shares of Jazz Pharmaceuticals during the fourth quarter worth $38,000. Danske Bank A S purchased a new stake in shares of Jazz Pharmaceuticals in the third quarter valued at $40,000. Geneos Wealth Management Inc. grew its position in shares of Jazz Pharmaceuticals by 57.6% in the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 137 shares during the period. Finally, Caitong International Asset Management Co. Ltd grew its position in shares of Jazz Pharmaceuticals by 1,383.3% in the third quarter. Caitong International Asset Management Co. Ltd now owns 356 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 332 shares during the period. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently commented on JAZZ shares. Leerink Partners lifted their price objective on Jazz Pharmaceuticals from $215.00 to $225.00 and gave the company an “outperform” rating in a research report on Wednesday, April 22nd. Royal Bank Of Canada raised their price target on Jazz Pharmaceuticals from $195.00 to $258.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 6th. Barclays raised their price target on Jazz Pharmaceuticals from $225.00 to $234.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. Robert W. Baird set a $252.00 price target on Jazz Pharmaceuticals in a research note on Wednesday, May 6th. Finally, Bank of America raised their price target on Jazz Pharmaceuticals from $263.00 to $275.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Jazz Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $241.53.

Insiders Place Their Bets

In other news, EVP Neena M. Patil sold 55,600 shares of Jazz Pharmaceuticals stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $191.56, for a total value of $10,650,736.00. Following the transaction, the executive vice president directly owned 56,862 shares of the company’s stock, valued at $10,892,484.72. The trade was a 49.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CAO Patricia Carr sold 1,287 shares of Jazz Pharmaceuticals stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $182.94, for a total value of $235,443.78. Following the completion of the transaction, the chief accounting officer directly owned 6,512 shares in the company, valued at $1,191,305.28. This represents a 16.50% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 74,015 shares of company stock worth $14,180,486. 4.30% of the stock is owned by insiders.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $239.83 on Monday. Jazz Pharmaceuticals PLC has a 52-week low of $105.00 and a 52-week high of $243.32. The firm has a fifty day moving average of $202.44 and a 200-day moving average of $180.29. The stock has a market capitalization of $15.05 billion, a PE ratio of -11,985.51, a P/E/G ratio of 0.43 and a beta of 0.27. The company has a quick ratio of 1.85, a current ratio of 2.04 and a debt-to-equity ratio of 0.95.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. The company had revenue of $1.07 billion during the quarter. On average, analysts anticipate that Jazz Pharmaceuticals PLC will post 20.75 EPS for the current year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.